Asuragen, Inc. Licenses Roche Molecular Systems, Inc.'s Real-time Quantitative PCR Technology for Clinical Gene Expression Profiling

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen Pharmacogenomic Services, a molecular biology and human clinical trials service provider, has received a license from Roche Molecular Systems for clinical gene expression profiling and DNA analysis utilizing Roche's real-time quantitative PCR technology (qRT-PCR, qPCR). This agreement provides Asuragen access to intellectual property rights that broaden its clinical testing capabilities.

Back to news